Pattern of MEF2B expression in lymphoid tissues and in malignant lymphomas

Dóra Krenács, Zita Borbényi, Judit Bedekovics, G. Méhes, E. Bagdi, L. Krenács

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Myocyte enhancer binding factor 2 B (MEF2B) is a member of the evolutionary conserved transcription family MEF2. MEF2B has been shown to directly control biological activity of the B cell lymphoma 6 (BCL6) gene in germinal center (GC) B cells. To validate MEF2B as an immunohistochemical marker, we studied a large consecutive series of hyperplastic lymphoid tissues (n = 38) and malignant lymphoproliferative conditions (n = 471), including all major categories of B and T cell neoplasms. In hyperplastic lymphoid tissues, MEF2B staining revealed intense and crisp nuclear expression confined to GC B cells. Unlike BCL6, MEF2B was not detected in follicular T cells. In addition, weak nuclear staining of plasma cells was noted. MEF2B staining labeled neoplastic cells of follicular lymphoma both in common and variant cases as well as in bone marrow biopsies with high sensitivity, while it was almost consistently negative in marginal zone lymphoma. Consistent MEF2B expression was found in Burkitt lymphoma and nodular lymphocyte predominant Hodgkin lymphoma as well as in the large majority of cases of mantle cell lymphoma and diffuse large cell B cell lymphoma. MEF2B protein expression showed a statistically significant association with that of BCL6 in cases of diffuse large B cell lymphoma, not otherwise specified. We conclude that MEF2B is a valuable marker of normal GC B cells, potentially useful in differential diagnosis of small B cell lymphomas.

Original languageEnglish
Pages (from-to)345-355
Number of pages11
JournalVirchows Archiv
Volume467
Issue number3
DOIs
Publication statusPublished - Oct 1 2015

Fingerprint

MEF2 Transcription Factors
Lymphoid Tissue
Lymphoma
B-Cell Lymphoma
Germinal Center
B-Lymphocytes
Staining and Labeling
T-Lymphocytes
Mantle-Cell Lymphoma
Follicular Lymphoma
Burkitt Lymphoma
Lymphoma, Large B-Cell, Diffuse
B-Cell Chronic Lymphocytic Leukemia
Plasma Cells
Hodgkin Disease
Differential Diagnosis
Bone Marrow

Keywords

  • Germinal center B cell-derived lymphomas
  • Germinal center B cells
  • MEF2B protein expression

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Cell Biology
  • Molecular Biology
  • Medicine(all)

Cite this

Pattern of MEF2B expression in lymphoid tissues and in malignant lymphomas. / Krenács, Dóra; Borbényi, Zita; Bedekovics, Judit; Méhes, G.; Bagdi, E.; Krenács, L.

In: Virchows Archiv, Vol. 467, No. 3, 01.10.2015, p. 345-355.

Research output: Contribution to journalArticle

Krenács, Dóra ; Borbényi, Zita ; Bedekovics, Judit ; Méhes, G. ; Bagdi, E. ; Krenács, L. / Pattern of MEF2B expression in lymphoid tissues and in malignant lymphomas. In: Virchows Archiv. 2015 ; Vol. 467, No. 3. pp. 345-355.
@article{76ca7b48afd04e549f8ba27b2b62433a,
title = "Pattern of MEF2B expression in lymphoid tissues and in malignant lymphomas",
abstract = "Myocyte enhancer binding factor 2 B (MEF2B) is a member of the evolutionary conserved transcription family MEF2. MEF2B has been shown to directly control biological activity of the B cell lymphoma 6 (BCL6) gene in germinal center (GC) B cells. To validate MEF2B as an immunohistochemical marker, we studied a large consecutive series of hyperplastic lymphoid tissues (n = 38) and malignant lymphoproliferative conditions (n = 471), including all major categories of B and T cell neoplasms. In hyperplastic lymphoid tissues, MEF2B staining revealed intense and crisp nuclear expression confined to GC B cells. Unlike BCL6, MEF2B was not detected in follicular T cells. In addition, weak nuclear staining of plasma cells was noted. MEF2B staining labeled neoplastic cells of follicular lymphoma both in common and variant cases as well as in bone marrow biopsies with high sensitivity, while it was almost consistently negative in marginal zone lymphoma. Consistent MEF2B expression was found in Burkitt lymphoma and nodular lymphocyte predominant Hodgkin lymphoma as well as in the large majority of cases of mantle cell lymphoma and diffuse large cell B cell lymphoma. MEF2B protein expression showed a statistically significant association with that of BCL6 in cases of diffuse large B cell lymphoma, not otherwise specified. We conclude that MEF2B is a valuable marker of normal GC B cells, potentially useful in differential diagnosis of small B cell lymphomas.",
keywords = "Germinal center B cell-derived lymphomas, Germinal center B cells, MEF2B protein expression",
author = "D{\'o}ra Kren{\'a}cs and Zita Borb{\'e}nyi and Judit Bedekovics and G. M{\'e}hes and E. Bagdi and L. Kren{\'a}cs",
year = "2015",
month = "10",
day = "1",
doi = "10.1007/s00428-015-1796-6",
language = "English",
volume = "467",
pages = "345--355",
journal = "Virchows Archiv - A Pathological Anatomy and Histopathology",
issn = "0945-6317",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Pattern of MEF2B expression in lymphoid tissues and in malignant lymphomas

AU - Krenács, Dóra

AU - Borbényi, Zita

AU - Bedekovics, Judit

AU - Méhes, G.

AU - Bagdi, E.

AU - Krenács, L.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Myocyte enhancer binding factor 2 B (MEF2B) is a member of the evolutionary conserved transcription family MEF2. MEF2B has been shown to directly control biological activity of the B cell lymphoma 6 (BCL6) gene in germinal center (GC) B cells. To validate MEF2B as an immunohistochemical marker, we studied a large consecutive series of hyperplastic lymphoid tissues (n = 38) and malignant lymphoproliferative conditions (n = 471), including all major categories of B and T cell neoplasms. In hyperplastic lymphoid tissues, MEF2B staining revealed intense and crisp nuclear expression confined to GC B cells. Unlike BCL6, MEF2B was not detected in follicular T cells. In addition, weak nuclear staining of plasma cells was noted. MEF2B staining labeled neoplastic cells of follicular lymphoma both in common and variant cases as well as in bone marrow biopsies with high sensitivity, while it was almost consistently negative in marginal zone lymphoma. Consistent MEF2B expression was found in Burkitt lymphoma and nodular lymphocyte predominant Hodgkin lymphoma as well as in the large majority of cases of mantle cell lymphoma and diffuse large cell B cell lymphoma. MEF2B protein expression showed a statistically significant association with that of BCL6 in cases of diffuse large B cell lymphoma, not otherwise specified. We conclude that MEF2B is a valuable marker of normal GC B cells, potentially useful in differential diagnosis of small B cell lymphomas.

AB - Myocyte enhancer binding factor 2 B (MEF2B) is a member of the evolutionary conserved transcription family MEF2. MEF2B has been shown to directly control biological activity of the B cell lymphoma 6 (BCL6) gene in germinal center (GC) B cells. To validate MEF2B as an immunohistochemical marker, we studied a large consecutive series of hyperplastic lymphoid tissues (n = 38) and malignant lymphoproliferative conditions (n = 471), including all major categories of B and T cell neoplasms. In hyperplastic lymphoid tissues, MEF2B staining revealed intense and crisp nuclear expression confined to GC B cells. Unlike BCL6, MEF2B was not detected in follicular T cells. In addition, weak nuclear staining of plasma cells was noted. MEF2B staining labeled neoplastic cells of follicular lymphoma both in common and variant cases as well as in bone marrow biopsies with high sensitivity, while it was almost consistently negative in marginal zone lymphoma. Consistent MEF2B expression was found in Burkitt lymphoma and nodular lymphocyte predominant Hodgkin lymphoma as well as in the large majority of cases of mantle cell lymphoma and diffuse large cell B cell lymphoma. MEF2B protein expression showed a statistically significant association with that of BCL6 in cases of diffuse large B cell lymphoma, not otherwise specified. We conclude that MEF2B is a valuable marker of normal GC B cells, potentially useful in differential diagnosis of small B cell lymphomas.

KW - Germinal center B cell-derived lymphomas

KW - Germinal center B cells

KW - MEF2B protein expression

UR - http://www.scopus.com/inward/record.url?scp=84940611406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940611406&partnerID=8YFLogxK

U2 - 10.1007/s00428-015-1796-6

DO - 10.1007/s00428-015-1796-6

M3 - Article

VL - 467

SP - 345

EP - 355

JO - Virchows Archiv - A Pathological Anatomy and Histopathology

JF - Virchows Archiv - A Pathological Anatomy and Histopathology

SN - 0945-6317

IS - 3

ER -